Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A best practice guide for conducting healthy food retail research: A resource for researchers and health promotion practitioners.
Scapin T, Boelsen-Robinson T, Naughton S, Ananthapavan J, Blake M, Ferguson M, Gomez-Donoso C, Gupta A, Hobbs V, McMahon EJ, Romaniuk H, Sacks G, Thompson J, Alston L, Backholer K, Bennett R, Brimblecombe J, Chan J, Duus KS, Huse O, Maganja D, Marshall J, Orellana L, Rosewarne E, Schultz S, Sievert K, Sherriff S, Tran HNQ, Vargas C, Wu JHY, Peeters A, Cameron AJ. Scapin T, et al. Among authors: marshall j. Obes Rev. 2025 Jan 29:e13870. doi: 10.1111/obr.13870. Online ahead of print. Obes Rev. 2025. PMID: 39887915
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation (PART 3A - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance PART 3B - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).
Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X, Sonderegger I, Smeraglia J, Huleatt J, Loo L, Beaver C, DelCarpini J, Dessy F, Diebold S, Fiscella M, Garofolo F, Grimaldi C, Gupta S, Hou V, Irwin C, Jani D, Joseph J, Kalina W, Kar S, Kavita U, Lu Y, Marshall JC, Mayer C, Mora J, Nolan K, Peng K, Riccitelli N, Scully I, Seitzer J, Stern M, Wadhwa M, Xu Y, Verthelyi D, Sumner G, Clements-Egan A, Chen C, Gorovits B, Torri A, Baltrukonis D, Gunn G, Ishii-Watabe A, Kramer D, Kubiak RJ, Mullins G, Pan L, Partridge MA, Poetzl J, Rasamoelisolo M, Sirtori FR, Richards S, Saad OM, Shao W, Song Y, Song S, Staack RF, Wu B, Manangeeswaran M, Thacker S. Tounekti O, et al. Among authors: marshall jc. Bioanalysis. 2025 Jan 25:1-45. doi: 10.1080/17576180.2024.2439229. Online ahead of print. Bioanalysis. 2025. PMID: 39862111
Vitronectin regulates lung tissue remodeling and emphysema in chronic obstructive pulmonary disease.
Liu G, Hsu AC, Geirnaert S, Cong C, Nair PM, Shen SS, Marshall J, Haw TJ, Fricker M, Philp AM, Hansbro NG, Pavlidis S, Guo Y, Burgess JK, Castellano L, Ieni A, Caramori G, Oliver BG, Chung KF, Adcock IM, Knight DA, Polverino F, Bracke K, Wark PA, Hansbro PM. Liu G, et al. Among authors: marshall j. Mol Ther. 2025 Jan 21:S1525-0016(25)00036-X. doi: 10.1016/j.ymthe.2025.01.032. Online ahead of print. Mol Ther. 2025. PMID: 39838644
7,109 results